|
PanACEA - STEP2C-01 |
enrolling |
|
CRUSH-TB |
enrolling |
|
PRESCIENT Trial |
enrolling |
|
DRAMATIC Trial |
enrolling |
|
NC-009 Trial |
enrolling |
|
PAN-TB XBQS Trial |
enrolling |
|
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults |
enrolling |
|
Phase 2: EBA, Safety and Tolerability of Sanfetrinem Cilexetil |
enrolling |
|
Phase 2 EBA: bEto TB |
enrolling |
|
endTB-Q |
in data analysis |
|
TBI-223 Phase 1 MAD |
enrolling |
|
Phase 2. Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis |
submitted for publication |
|
Phase 2. Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis |
enrolling |
|
Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB |
enrolling |
|
DECODE- Delpazolid Dose-Finding and Combination Development Trial |
all patients enrolled |
|
Sutezolid Dose-finding and Combination Evaluation (SUDOCU) |
all patients enrolled |
|
Phase 2: IMPACT-TB Safety, Pharmacokinetics & Hematologic Effect of Imatinib |
enrolling |
|
Phase 2b: StAT-TB (Statin Adjunctive Therapy for TB) |
in data analysis |
|
Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286 |
enrolling |
|
Phase 1 Safety, Tolerability and Pharmacokinetics of BVL-GSK098 |
submitted for publication |
|
EBA, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis |
published |
|
BEAT-TB Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis |
submitted for publication |
|
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults |
published |
|
Phase 1 Safety, Tolerability, and Pharmacokinetics of SPR720 |
published |
|
BTZ-043 Multiple Ascending Dose / EBA |
submitted for publication |
|
OPC-167832 Phase 1 / 2 EBA |
published |
|
NC-005 |
published |
|
SimpliciTB |
published |
|
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371. |
published |
|
Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 |
in data analysis |
|
Phase 2 Telacebec (Q203) EBA |
published |
|
Phase 2a Study of PBTZ169 |
|
|
TRUNCATE-TB |
published |
|
SimpliciTB-Pa-M-Z) NC-008 |
study in development |
|
ZeNix (B-Pa-L) NC-007 |
submitted for publication |
|
PredictTB |
enrolling |
|
Phase 2 Safety, Efficacy & Biomarker Response of HDTs Added to Standard Therapy |
published |
|
TB-PRACTECAL |
published |
|
NexGen EBA |
enrolling |
|
RIFASHORT |
published |
|
ACTG 5343 Bedaquiline - Delamanid with MBT for MDR |
published |
|
NExT Trial: Bedaquiline - Linezolid with OBR MDR |
early termination |
|
endTB |
published |
|
ReDEFINe High-Dose RIF for Meningitis |
in data analysis |
|
High-Dose Rifampin |
published |
|
PanACEA-MAMS-TB-01 |
all patients enrolled |
|
PanACEA - RUNMC - HR1 2007.23011.01 |
published |
|
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients |
enrolling |
|
Nix-TB (B-Pa-L) |
all patients enrolled |
|
Q203 Phase 1a Q203-TB-PI-US001 |
in data analysis |
|
Q203 Phase 1b Q203-TB-PI-US002 |
all patients enrolled |
|
Nitzoxanide NZT001 14-day EBA |
all patients enrolled |
|
TBTC Study 31 ACTG 5349 4-month treatment regimens |
all patients enrolled |
|
Rifapentine TBTC Study 29 |
published |
|
TBA 354 Phase 1b Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects |
early termination |
|
TBA-354 Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects |
all patients enrolled |
|
Celecoxib Clinical Study WBA |
in data analysis |
|
AZD5847 Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis |
published |
|
B1171001 |
published |
|
Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers |
in data analysis |
|
ACTG 5306 Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritona |
enrolling |
|
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis |
in data analysis |
|
B1171002 |
published |
|
B1171003 |
published |
|
PanACEA-MAMS-TB-01 |
published |
|
LMU-IMPH-SQ109-01 |
published |
|
SQ109-CP001 |
published |
|
09-0111 N01AI80024C |
published |
|
Traitement du Sida |
submitted for publication |
|
Phase 1 Effect of PA-824 and PA-824 plus Moxifloxacin on the QTc Interval in Health Volunteers |
in data analysis |
|
ACTG 5306 Phase I Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin |
enrolling |
|
A Phase IIa, Open Label Study to Determine the EBA, Extended EBA and Pharmacokinetic Study of LL3858 for the Treatment of Newly Diagnosed Sputum Smear-Positive Pulmonary TB |
study in development |
|
Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients |
enrolling |
|
A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis. |
all patients enrolled |
|
Controlled comparison of two moxifloxacin containing treatment shortening regimens with the standard regimen in pulmonary TB |
all patients enrolled |
|
NC002 Phase II Trial to Evaluate the Efficacy, Safety and Tolerability of the Following: PA-824 Plus Moxifloxacin Plus Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Patients |
|
|
NC001 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) |
submitted for publication |
|
NC003 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) |
enrolling |
|
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis |
published |
|
NIH: A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects |
published |
|
Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis |
published |
|
TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tube |
submitted for publication |
|
TBTC Study 30PK Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis |
submitted for publication |
|
NC005 |
enrolling |
|
TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection |
published |
|
Perchlozone tablets |
submitted for publication |
|
TBTC Study 33/iAdhere: AdherenceC |
in data analysis |
|
TBTC Study 32, Opti-Q |
enrolling |
|
NC-003 |
published |
|
Meropenem, Faropenem Phase 2 EBA, TASK-001 |
published |
|
Faro-WBA |
submitted for publication |
|
Safety and efficacy of blocking IL-4 with pascolizumab in patients receiving standard combination therapy for pulmonary tuberculosis (TB): a randomized, double-blind, placebo-controlled, proof-of-conc |
enrolling |
|
Single Dose, Phase 1 |
published |
|
NC003 |
enrolling |
|
STAND |
all patients enrolled |
|
TMC207-TiDP13-208 |
published |
|
TMC207-TiDP13-C209 |
published |
|
STREAM Trial Stage 2 |
submitted for publication |
|
TMC207TBC1002 |
published |
|
TMC207-TBC211 |
study in development |
|
242-07-204 |
published |
|
Delamanid with OBR for MDR TB |
in data analysis |
|
Pediatric PK and Safety Trial Delamanid in MDR TB |
enrolling |
|
NC002 |
|
|
NC001 |
submitted for publication |
|
Multiple Dose, Phase 1 |
published |
